» Articles » PMID: 33160859

MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Overview
Journal Acad Radiol
Specialty Radiology
Date 2020 Nov 8
PMID 33160859
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale And Objectives: There are limited data on pretreatment imaging features that can predict response to neoadjuvant chemotherapy (NAC). To extract volumetric pretreatment MRI radiomics features and assess corresponding associations with breast cancer molecular subtypes, pathological complete response (pCR), and residual cancer burden (RCB) in patients treated with NAC.

Materials And Methods: In this IRB-approved study, clinical and pretreatment MRI data from patients with biopsy-proven breast cancer who received NAC between September 2009 and July 2016 were retrospectively analyzed. Tumors were manually identified and semi-automatically segmented on first postcontrast images. Morphological and three-dimensional textural features were computed, including unfiltered and filtered image data, with spatial scaling factors (SSF) of 2, 4, and 6 mm. Wilcoxon rank-sum tests and area under the receiver operating characteristic curve were used for statistical analysis.

Results: Two hundred and fifty nine patients with unilateral breast cancer, including 73 (28.2%) HER2+, 112 (43.2%) luminal, and 74 (28.6%) triple negative breast cancers (TNBC), were included. There was a significant difference in the median volume (p = 0.008), median longest axial tumor diameter (p = 0.009), and median longest volumetric diameter (p = 0.01) among tumor subtypes. There was also a significant difference in minimum signal intensity and entropy among the tumor subtypes with SSF = 4 mm (p = 0.009 and p = 0.02 respectively) and SSF = 6 mm (p = 0.007 and p < 0.001 respectively). Additionally, sphericity (p = 0.04) in HER2+ tumors and entropy with SSF = 2, 4, 6 mm (p = 0.004, 0.02, 0.047 respectively) in luminal tumors were significantly associated with pCR. Multiple features demonstrated significant association (p < 0.05) with pCR in TNBC and with RCB in luminal tumors and TNBC, with standard deviation of intensity with SSF = 6 mm achieving the highest AUC (AUC = 0.734) for pCR in TNBC.

Conclusion: MRI radiomics features are associated with different molecular subtypes of breast cancer, pCR, and RCB. These features may be noninvasive imaging biomarkers to identify cancer subtype and predict response to NAC.

Citing Articles

Harnessing Artificial Intelligence to Enhance Global Breast Cancer Care: A Scoping Review of Applications, Outcomes, and Challenges.

Chia J, He G, Ngiam K, Hartman M, Ng Q, Goh S Cancers (Basel). 2025; 17(2).

PMID: 39857979 PMC: 11764353. DOI: 10.3390/cancers17020197.


Predicting response of hepatoblastoma primary lesions to neoadjuvant chemotherapy through contrast-enhanced computed tomography radiomics.

Yang Y, Wang H, Si J, Zhang L, Ding H, Wang F J Cancer Res Clin Oncol. 2024; 150(5):223.

PMID: 38691204 PMC: 11063102. DOI: 10.1007/s00432-024-05746-x.


Radiomic model based on magnetic resonance imaging for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Yu Y, Wang Z, Wang Q, Su X, Li Z, Wang R Front Oncol. 2024; 13:1249339.

PMID: 38357424 PMC: 10865896. DOI: 10.3389/fonc.2023.1249339.


Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review.

Alamoodi M Eur J Breast Health. 2024; 20(1):8-14.

PMID: 38187111 PMC: 10765459. DOI: 10.4274/ejbh.galenos.2023.2023-11-2.


Evaluation of molecular receptors status in breast cancer using an mpMRI-based feature fusion radiomics model: mimicking radiologists' diagnosis.

Lai S, Liang F, Zhang W, Zhao Y, Li J, Zhao Y Front Oncol. 2023; 13:1219071.

PMID: 38074664 PMC: 10698551. DOI: 10.3389/fonc.2023.1219071.